Treatment of gastrointestinal fistulas with Sandostatin.
Pharmacological treatment of patients with enterocutaneous fistulas aims at reducing output, increasing the chance of spontaneous closure and reducing the time of fistula closure. Our initial experience with octreotide suggests that this drug effectively reduces output of established enterocutaneous fistulas when compared with a placebo in patients on parenteral nutrition. Output reduction was independent of the basal output. Likewise, this somatostatin analogue was shown to accelerate fistula closure in a series of 27 patients treated with the drug after having received parenteral nutrition for a mean of 25 days. When compared with a historical series, the rate of spontaneous fistula closure was not modified by octreotide.
Sitges-Serra
A
A
Department of Surgery, Hospital Universitari de Mar, Universitat Autònoma de Barcelona, Spain.
Guirao
X
X
Pereira
J A
JA
Nubiola
P
P
D004311:Double-Blind Method; D004378:Duodenal Diseases / Q000188:drug therapy; D005260:Female; D005402:Fistula / Q000188:drug therapy*; D006801:Humans; D007077:Ileal Diseases / Q000188:drug therapy; D007412:Intestinal Fistula / Q000188:drug therapy*; D007579:Jejunal Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010288:Parenteral Nutrition; D011183:Postoperative Complications / Q000188:drug therapy*; D011446:Prospective Studies; D012871:Skin Diseases / Q000188:drug therapy*; D013272:Stomach Diseases / Q000188:drug therapy*
D015282:Octreotide